Insider Trading April 3, 2026

Amalgamated Financial EVP Sells $195K in Stock; Q4 2025 Revenue Tops Estimates

Sean Searby executed planned disposals under a 10b5-1 arrangement as company posted an EPS in line with estimates and a modest revenue beat

By Priya Menon AMAL
Amalgamated Financial EVP Sells $195K in Stock; Q4 2025 Revenue Tops Estimates
AMAL

Sean Searby, executive vice president and chief information and operations officer at Amalgamated Financial Corporation (NASDAQ: AMAL), sold 4,948 shares on April 1, 2026, for roughly $195,048 under an existing Rule 10b5-1 trading plan. Separately, 330 shares were withheld related to a vested restricted stock unit installment. The company reported fourth-quarter 2025 results that matched EPS expectations at $0.91 and recorded revenue of $87.91 million, a 2.98% upside versus forecasts.

Key Points

  • Sean Searby, Amalgamated Financial EVP and chief information and operations officer, sold 4,948 shares on April 1, 2026, for about $195,048 at a weighted average price of $39.4196, with trade prices between $39.155 and $39.77.
  • An additional 330 shares were withheld related to the vesting of a restricted stock unit installment awarded on April 1, 2024, sold at $39.08 for $12,896.
  • Amalgamated Financial reported fourth-quarter 2025 EPS of $0.91, in line with expectations, and revenue of $87.91 million, a 2.98% beat; there were no analyst upgrades or downgrades following the release.

Sean Searby, who serves as executive vice president and chief information and operations officer at Amalgamated Financial Corporation, reported the sale of 4,948 shares of the bank holding companys common stock on April 1, 2026. The transactions generated approximately $195,048, executed at a weighted average price of $39.4196 per share, with trade prices ranging from $39.155 to $39.77 across multiple transactions.

In a separate entry on the same Form 4 filing with the Securities and Exchange Commission, Searby also recorded the disposition of 330 shares at $39.08 per share, producing proceeds of $12,896. Those 330 shares were withheld in connection with the vesting of a restricted stock unit installment originally awarded to the reporting person on April 1, 2024.

Following these moves, Searby is listed as the direct owner of 23,055.26 shares of Amalgamated Financial Corporation common stock. The sales were carried out under a pre-established Rule 10b5-1 trading plan that the reporting person adopted on April 29, 2025, according to the filing.


Separately, the companys fourth-quarter 2025 financial results were disclosed, showing earnings per share of $0.91, which matched analyst expectations. Revenue for the period totaled $87.91 million, representing a 2.98% positive surprise versus consensus forecasts. The report notes that the revenue outperformance was a notable aspect of the release and that market participants reacted with positive sentiment. The earnings release did not trigger any analyst upgrades or downgrades, according to the summary of recent developments.

Market observers continue to track both insider activity and the companys reported financials. The filing documents and the quarterly results form part of an ongoing set of updates that investors and analysts are monitoring as they assess Amalgamated Financial Corporations near-term performance.

Risks

  • The filing does not provide detail on the motivations behind the securities dispositions beyond noting they were executed under an existing Rule 10b5-1 trading plan - this leaves the rationale for timing and sizing of the sales unclear.
  • Investor reaction to insider selling and to quarterly results can vary; the report notes positive sentiment around the revenue beat but does not indicate any consequent changes in analyst recommendations.
  • Limited forward-looking commentary in the filing and the earnings summary leaves ongoing market assessment and near-term outlook subject to uncertainty as participants continue to monitor subsequent disclosures.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026